Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
Abstract While type I interferon (IFN) is best known for its key role against viral infection, accumulating preclinical and clinical data indicate that robust type I IFN production in the tumor microenvironment promotes cancer immunosurveillance and contributes to the efficacy of various antineoplas...
Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formáid: | Alt |
Teanga: | English |
Foilsithe / Cruthaithe: |
Nature Publishing Group
2023-03-01
|
Sraith: | Cell Death and Disease |
Rochtain ar líne: | https://doi.org/10.1038/s41419-023-05728-w |